

Log Unit Inhibition
0
1
2
3
4
5
6
7
1U/ml
0.1U/ml
10 U/ml
1 U/ml
100 U/ml
10 U/ml
10 mg/ml
1 mg/ml
0.1 mg/ml
10 mg/ml
1 mg/ml
0.1 mg/ml
20 mU/ml
2 mU/ml
0.2 mU/ml
50 mU/ml
10 mU/ml
10 mg/ml
1 mg/ml
PLA
PLC
PLD
Trypsin
Proteinase K
Bromelian
Papain
a-chymotrypsin
Enzymes/Concentrations

FIG. 1A



Log Unit Inhibition
6
5
4
3
2
1
0
100 mU/ml
10 mU/ml
1 mU/ml
0.1 mU/ml
1000 mg/ml
100 mg/ml
10 mg/ml
100 mU/ml
10 mU/ml
1 U/ml
0.1 U/ml
1 U/ml
0.1 U/ml
1 mM/ml
0.1 mM/ml
1000 mg/ml
100 mg/ml
1000 mg/ml
100 mg/ml
1000 mg/ml
100 mg/ml
EH
OG
MA
FU
Hep I
Hep III
SP
WGA
PHA
ConA
Enzymes/Concentrations

FIG. 1B




FIG. 2A




FIG. 2B




FIG. 3




FIG. 4




FIG. 5A



FIG. 5B




FIG. 5C




FIG. 6




FIG. 7




FIG. 8A




FIG. 8B




FIG. 9




FIG. 10



% reduction in virus infection
100
90
80
70
60
50
40
30
20
10
0
25ug/ml
2.5ug/ml
0.25ug/ml
Concentration of functional blocking integrin antibodies
INTB1
INTB2
INTB31
INTB32
INTB4
INTB5
ALPHAV
ALPHAV/B3
ALPHAV/B5
% reduction of virus infection
100
90
80
70
60
50
40
30
20
10
0
25ug/ml
2.5ug/ml
0.25ug/ml
Concentration of functional blocking integrin antibodies
INTB1
INTB2
INTB31
INTB32
INTB4
INTB5
APLHAV
ALPHAV/B3
ALPHAV/B5

FIG. 11



% inhibition of JEV entry
100
90
80
70
60
50
40
30
20
10
0
INTB1
INTB2
INTB3
INTB4
INTB5
ALPHAV
ALPHAV/B3
ALPHAV/B5
Anti-integrin antibodies

FIG. 12



100
90
80
70
60
50
40
30
20
10
0
% reduction of virus infection
WNV
JEV
3 mM
5 mM
7mM
10 mM
12 mM
Concentration of EDTA

FIG. 13



100
90
80
70
60
50
40
30
20
10
0
% reduction of virus infection
WNV
JEV
RGE1
RGD1
FIBRO1
VITRO1
LAMININ1
CHONSUL1
Heparin
Competitive ligands binding

FIG. 14




FIG. 15




FIG. 16



100
90
80
70
60
50
40
30
20
10
0
% inhibition of WNV entry
1ug
2.5 ug
4 ug
5 ug
concentration of siRNA used
INTaphaV1
INT alpha V2
INT B31
INT B32
GAPDH

FIG. 17



25
20
15
10
5
0
-5
ATPB1
ATPB2
ATPA1
ATPA2
CALTYPE1
VATPASE1
VATPASE2

FIG. 18



100
90
80
70
60
50
40
30
20
10
0
% reduction virus entry
10ug/ml
8ug/ml
5ug/ml
2ug/ml
Concentration of anti-neurotensin receptor

FIG. 19



WNV
100
90
80
70
60
50
40
30
20
10
0
% inhibition of virus entry
1 ug/ml
3 ug/ml
5 ug/ml
Concentration of neurotensin
WNV

FIG. 20



A
B

FIG. 21



A
1 2 3 4 5
60 kDa
50 kDa
40 kDa
20 kDa
15 kDa
B
1 2 3 4
60 kDa
50 kDa
40 kDa
20 kDa
15 kDa

FIG. 22



100
90
80
70
60
50
40
30
20
10
0
% inhibition of virus entry
WNV+DIII
WNV+BSA
Dengue 2 V + DIII
100ug/ml
50ug/ml
25ug/ml
10ug/ml
5ug/ml
Concentration of inhibitor(s)

FIG. 23



60 kDa
50 kDa
40 kDa
20 kDa
15 kDa

FIG. 24



110.00
100.00
90.00
80.00
70.00
60.00
50.00
40.00
30.00
20.00
10.00
0.00
% inhibition of virus infection
2
4
8
16
32
64
128
256
512
1024
2048
4096
8192
Dilution
Mouse anti-DIII protein
Pre-immunized sera

FIG. 25